US FDA Approves AbbVie's Tavapadon for Parkinson's Disease
核心洞察
The U.S. FDA has approved AbbVie's tavapadon for adults with Parkinson's disease (搜索), according to the regulator's website.
Tavapadon is a once-a-day oral pill that AbbVie obtained through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.
The drug will be marketed as Juvmo (搜索) and works by mimicking dopamine, which declines in people with Parkinson's disease (搜索).
The U.S. Food and Drug Administration has approved AbbVie's tavapadon for adults with Parkinson's disease (搜索), according to the regulator's website. The drug is a once-a-day pill and will be sold under the brand name Juvmo (搜索).
AbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023. The approval was based on data from AbbVie's late-stage trial program, which showed the drug improved symptoms in patients with the disease. Tavapadon works by mimicking dopamine, a brain chemical that naturally decreases in people with Parkinson's. Common side effects reported in the trials included nausea, dizziness and headache.
Parkinson's is a long-term brain condition that gradually damages movement control, often causing tremors, stiffness and balance issues. More than 11 million people live with the disease worldwide, according to AbbVie. AbbVie did not respond to a Reuters request for comment on the drug's launch and pricing.